Q1. Medical Affairs has moved from a support function to a strategic pillar alongside R&D and commercial across the pharmaceutical industry. In your view, what specifically changed for pharma organisations, and what does the Medical Affairs mandate look like today that it did not ten years ago?
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on. Through ongoing scientific exchange, Medical can communicate the science while also identifying unmet needs, evidence gaps, and perspectives from the field and bringing those insights back into the organization. This communication bridge allows Medical to help shape strategy earlier, working closely with R&D while maintaining an independent scientific voice alongside R&D and commercial. That evolution has made Medical Affairs an important partner between external clinical practice and internal decision-making.
Q2. Volume is easy; signal is hard. How do pharma Medical Affairs teams guard against confirmation bias, over-indexing on the loudest voices, and the pull toward surfacing insights that leadership already wants to hear?
Guarding against bias starts with listening broadly and gathering perspectives across diverse geographies, practice settings and patient populations. The goal isn’t to find the most common answer. It’s to understand whether what you’re hearing represents the breadth of clinical reality. Conflicting perspectives can both be valid depending on their context. That requires curious, active listening and a culture where Medical feels empowered to challenge internal assumptions, even when what we hear may contradict what an organization expects.
Q3. Can you share an example — anonymised as needed — where a field insight materially altered a global pharmaceutical decision, whether an evidence-generation plan, a trial design, a data-communication sequence, or a launch narrative?
There’s a lot that goes into launching a new treatment, with teams preparing well in advance around what they anticipate physicians and patients will need. During one launch, repeated field insights showed us that both the scientific questions and the physician audiences with the greatest need for engagement were different from what we had anticipated. That challenged some of our initial assumptions and led us to reassess our approach, communication priorities and broader engagement strategy. It reinforced for me that strategy should never be static. Field insights allow us to test our assumptions against clinical reality and change course when those assumptions don’t hold.
Q4. What KPIs actually prove the insight function is working? Many pharma teams still report insight counts, which says more about MSL activity than about influence on pharmaceutical strategy.
I think the real measure of an insight function is its impact on Medical Affairs strategy. Insight volume tells you about activity, but not necessarily value. I would look at how priority themes are actually traveling through the organization: where they were escalated, what decisions they informed, and what actions followed. Those might include changes to evidence generation priorities, scientific communications, stakeholder engagement, or educational resources. Ultimately, what matters is being able to trace meaningful insights to strategic influence, rather than creating metrics that simply reward more activity.
Q5. The traditional tiered KOL model is under pressure in pharma. How has the stakeholder map expanded — digital opinion leaders, community prescribers, patient advocacy groups, HTA and payer scientific advisors — and how should pharmaceutical companies allocate scarce MSL time across them?
The stakeholder landscape has expanded beyond the traditional academic KOL, and Medical Affairs teams have evolved alongside it. Many organizations have now created specialized engagement roles focused on areas like patient advocacy and digital engagement, allowing teams to distribute stakeholder engagement across the right expertise rather than continually expanding the MSL remit. Not every relationship should become an MSL responsibility. ] MSLs should prioritize stakeholders based on strategic relevance and scientific influence, specifically those shaping research, evidence generation and clinical practice, while maintaining enough breadth to capture unmet needs from community settings. The goal is to match the right type of Medical engagement to the right stakeholder.
Q6. Leading experts increasingly want to co-create rather than advise — co-authoring, shaping endpoints, designing real-world evidence studies. How far can a pharmaceutical company go down that road, and where does the relationship need clear guardrails?
Co-creation is most valuable when it improves the scientific relevance of the work, but it only works when roles are clear. For company-sponsored research, external experts can add enormous value when they are engaged early enough to meaningfully shape and pressure-test endpoints, study design and clinical relevance before assumptions become embedded. For investigator-initiated studies, the investigator’s scientific independence has to remain intact, with the company’s role appropriately limited. Across both models, collaboration should sharpen the scientific question, not steer toward a preferred answer. Authorship, funding and conflicts of interest should be transparent and never used to incentivize a particular scientific outcome.
Q7. Compliance sits permanently in the room. How do pharma Medical Affairs teams keep scientific exchange rigorously non-promotional while still being valuable enough that a busy clinician takes the meeting?
Clinicians are navigating an enormous volume of emerging data while managing busy practices, and Medical can help them efficiently interpret complex science. That requires more than presenting favorable results. Credibility comes from being equally willing to discuss study limitations, negative data, safety, dosing and practical clinical questions, and from responding to what the clinician actually needs rather than driving toward a prescribing outcome. When scientific depth, objectivity and relevance are consistently demonstrated, the MSL becomes a trusted scientific resource.
Q8. Where does technology genuinely help pharma — CRM insight tagging, NLP on unstructured MSL notes, AI-assisted synthesis — and where is the pharmaceutical industry buying tools it has not yet built the process discipline to use?
Technology is only as good as its inputs, and in Medical Affairs, speed can’t replace scientific judgment. AI can add enormous value by processing information at a scale humans cannot, from scanning congress abstracts to synthesizing insights and accelerating scientific communications. But organizations need to standardize the process before they automate it. Information inputs matter, from how it is captured to how the output will be used. Scientific accuracy, context and relevance still require human judgment and traceability. The opportunity isn’t to automate Medical Affairs decision-making, but instead to automate time intensive work so teams have more time to interpret the science and make better decisions.
Q9. What elements of scientific strategy should be standardized globally – such as core scientific narratives and evidence standards – and what should be adapted locally to reflect differences in clinical practice, healthcare systems and healthcare needs?
Core scientific narratives, evidence standards and scientific accuracy should remain consistent globally, while local teams need flexibility to adapt the emphasis and engagement to their clinical environment. Local perspectives are necessary early on to help ensure the global framework is structured in a way that can work across different markets, but the detailed localization happens later. That’s where local country affiliates can account for differences in standards of care, healthcare systems and patient needs. Global scientific strategy should provide the common scientific foundation while giving local teams the flexibility to make it meaningful in their local environment.
Q10. What operating rhythm should global pharma Medical Affairs and country teams run on, so that insights travel upward as reliably as strategy travels downward?
Global-local communication should be a continuous two-way channel, not a one-time handoff. Local teams should be involved early enough for their perspectives to meaningfully shape global strategy. From there, regular touchpoints should continue as the strategy advances, giving affiliates visibility into what is changing and why, while creating a consistent channel for insights to travel back upward. Clear ownership is also critical: priority themes need designated champions responsible for synthesizing and escalating what matters. Teams should also close the loop at the thematic level by showing what they heard, what is influencing strategy and what they are continuing to monitor. That transparency reinforces the value of contributing insights and helps local teams engage more strategically.
Q11. Many pharmaceutical organisations still run publications, medical information, MSL materials and congress content as parallel workstreams. How do you enforce a single core scientific narrative across all of them — and how is pharma publication planning changing with preprints, plain language summaries, open access and digital dissemination?
When a pharmaceutical company engages externally, it should ultimately be telling one coherent scientific story. That’s why I see the core scientific narrative as the heart of scientific communications. It gives multiple internal cross-functional teams a shared foundation they can continually return to, while adapting it for their specific audiences. That narrative also has to evolve as new evidence emerges and the treatment landscape evolves. Publication planning is evolving in a similar way. The work doesn’t end when a manuscript is published. We also have to think about how people find, access and understand the science through open access, plain-language summaries and digital channels.
Q12. Congress strategy is one of the largest line items in a pharma Medical Affairs budget and one of the least rigorously evaluated. Beyond abstract counts and booth traffic, how should pharmaceutical companies measure return — and how fast does congress insight actually reach the teams who need it?
Measuring the value of a congress starts with defining clear scientific objectives before the meeting. Those objectives should determine which stakeholders you prioritize, the scientific engagements you pursue, how you leverage your booth presence, and ultimately how you define success and how it will be measured. For that reason, congress success should not be reduced to a single metric like booth traffic or meeting counts. The quality of scientific engagement, strength of stakeholder relationships, scientific presence and insights generated all matter depending on the objective. Those insights also lose value with time, so urgent signals should be escalated immediately, with priority themes synthesized within days while they can still inform decisions and scientific decision-making.
